Antisense oligonucleotide targeting tdp-43 mrna or pre-mrna

An antisense oligonucleotide or a pharmaceutically acceptable salt thereof, or a hydrate thereof, consisting of 15 to 22 nucleotides complementary to a nucleic acid comprising at least 15 consecutive bases in a target region selected from the group consisting of positions 194 to 217, 350 to 452, 500 to 612, 629 to 684, 689 to 732, 821 to 844, 874 to 972, 1089 to 1177, 1277 to 1338, 1349 to 1392, 1444 to 1537, 1544 to 1592, 1644 to 1697, 1769 to 1812, 1969 to 2012, 2051 to 2317, and 2469 to 2512 from the 5′ end of a base sequence of SEQ ID NO:

• 1,
• wherein an antisense oligonucleotide or a pharmaceutically acceptable salt thereof, or a hydrate thereof having a sequence consisting of a base sequence selected from the group consisting of SEQ ID NOs:
• 436 to 438, 440 to 449, 451 to 452, 454 to 455, and 472 to 474 is excluded, and
• an antisense oligonucleotide having a sequence consisting of a base sequence of SEQ ID NO:
• 450 or a pharmaceutically acceptable salt thereof, or a hydrate thereof, in which positions 2 to 3, 5 to 6, 10 to 14, 16, 18 and 20 from the 5′ end of the base sequence of SEQ ID NO:
• 450 are ENA:
• 2′-O,4′-C-ethylene bridged nucleic acid, and positions 1, 4, 7 to 9, 15, 17, and 19 are ribonucleotides comprising a 2′-OMe group, is excluded, and
• an antisense oligonucleotide having a sequence consisting of a base sequence of SEQ ID NO:
• 453 or a pharmaceutically acceptable salt thereof, or a hydrate thereof, in which positions 1 to 2, 4, 6, 8 to 9, 11 to 12, and 16 to 20 from the 5′ end of the base sequence of SEQ ID NO:
• 453 are ENA:
• 2′-O,4′-C-ethylene bridged nucleic, and positions 3, 5, 7, 10, and 13 to 15 are ribonucleotides comprising a 2′-OMe group, is excluded.